Vascular Endothelial Growth Factor Inhibitor [EPC]

136753 reported adverse events

Drugs of this class: RANIBIZUMAB AFLIBERCEPT BEVACIZUMAB BEVACIZUMAB-AWWB BEVACIZUMAB-BVZR BEVACIZUMAB-MALY RANIBIZUMAB-EQRN RANIBIZUMAB-NUNA ZIV-AFLIBERCEPT

These side effects are most commonly reported by patients taking drugs of the Vascular Endothelial Growth Factor Inhibitor [EPC] class:

#	Side effect	Count
0	DEATH	21139
1	OFF LABEL USE	8616
2	DIARRHOEA	6263
3	DISEASE PROGRESSION	5896
4	NAUSEA	5652
5	FATIGUE	5297
6	HYPERTENSION	5196
7	VOMITING	4404
8	VISUAL ACUITY REDUCED	3851
9	DRUG INEFFECTIVE	3602

See all common reactions for Vascular Endothelial Growth Factor Inhibitor [EPC]

Drugs of the Vascular Endothelial Growth Factor Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	RETINAL PIGMENT EPITHELIAL TEAR	468	0.8225
1	POLYPOIDAL CHOROIDAL VASCULOPATHY	224	0.8058
2	BACTERIAL ENDOPHTHALMITIS	50	0.7463
3	PSEUDOENDOPHTHALMITIS	56	0.7179
4	NON-INFECTIOUS ENDOPHTHALMITIS	412	0.6592
5	DIABETIC RETINAL OEDEMA	255	0.6538
6	SUBRETINAL FIBROSIS	95	0.6209
7	DETACHMENT OF RETINAL PIGMENT EPITHELIUM	435	0.6179
8	RETINAL THICKENING	84	0.6176
9	CHOROIDAL NEOVASCULARISATION	366	0.5932

See all enriched reactions for Vascular Endothelial Growth Factor Inhibitor [EPC]